Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Antisense regulation of atrial natriuretic peptide expression
Selvi Celik, … , J. Gustav Smith, Olof Gidlöf
Selvi Celik, … , J. Gustav Smith, Olof Gidlöf
Published September 10, 2019
Citation Information: JCI Insight. 2019;4(19):e130978. https://doi.org/10.1172/jci.insight.130978.
View: Text | PDF
Research Article Cardiology

Antisense regulation of atrial natriuretic peptide expression

  • Text
  • PDF
Abstract

The cardiac hormone atrial natriuretic peptide (ANP) is a central regulator of blood volume and a therapeutic target in hypertension and heart failure. Enhanced ANP activity in such conditions through inhibition of the degradative enzyme neprilysin has shown clinical efficacy but is complicated by consequences of simultaneous accumulation of a heterogeneous array of other hormones. Targets for specific ANP enhancement have not been available. Here, we describe a cis-acting antisense transcript (NPPA-AS1), which negatively regulates ANP expression in human cardiomyocytes. We show that NPPA-AS1 regulates ANP expression via facilitating NPPA repressor RE1-silencing transcription factor (REST) binding to its promoter, rather than forming an RNA duplex with ANP mRNA. Expression of ANP mRNA and NPPA-AS1 was increased and correlated in isolated strained human cardiomyocytes and in hearts from patients with advanced heart failure. Further, inhibition of NPPA-AS1 in vitro and in vivo resulted in increased myocardial expression of ANP, increased circulating ANP, increased renal cGMP, and lower blood pressure. The effects of NPPA-AS1 inhibition on NPPA expression in human cardiomyocytes were further marked under cell-strain conditions. Collectively, these results implicate the antisense transcript NPPA-AS1 as part of a physiologic self-regulatory ANP circuit and a viable target for specific ANP augmentation.

Authors

Selvi Celik, Mardjaneh Karbalaei Sadegh, Michael Morley, Carolina Roselli, Patrick T. Ellinor, Thomas Cappola, J. Gustav Smith, Olof Gidlöf

×

Figure 1

Tissue distribution of NPPA-AS1.

Options: View larger image (or click on image) Download as PowerPoint
Tissue distribution of NPPA-AS1.
(A) Schematic overview of the NPPA/NPPA...
(A) Schematic overview of the NPPA/NPPA-AS1 locus. Arrows indicate direction of transcription. Chromosomal position is indicated at the top (GRCh37/hg19 genome assembly). Expression of NPPA-AS1 (B) and NPPA (C) across 53 different human tissues based on RNA-Seq data from the GTEx database (v. 7). Cardiac tissues are highlighted. TPM, transcripts per million reads. (D) Expression of NPPA and NPPA-AS1 in left ventricular (LV, n = 22) and left atrial (LA, n = 101) tissue based on RNA-Seq data from the Myocardial Applied Genomics Network. FPKM, fragments per kilobase million.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts